Lexology January 18, 2024
Sheppard Mullin Richter & Hampton LLP

In one of the last guidances released in 2023, the Federal Food and Drug Administration (FDA) finalized guidance for direct-to-consumer (DTC) prescription drug advertisements, specifically advertisements in television and radio format (CCN Final Rule Guidance). The CCN Final Rule Guidance was released to advise small entities seeking to understand and comply with the standards established in the final rule, “Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format” (CCN Final Rule).

The CCN Final Rule, published in November 2023, establishes five key standards for the “major statement” which provides information related to the major side effects and contraindications of an prescription drug communicated directly to consumers....

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article